These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 37814332)

  • 1. The efficacy and ocular safety following aflibercept, conbercept, ranibizumab, bevacizumab, and laser for retinopathy of prematurity: a systematic review and meta-analysis.
    Chen J; Hao Q; Zhang J; Du Y; Chen H; Cheng X
    Ital J Pediatr; 2023 Oct; 49(1):136. PubMed ID: 37814332
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of different agents and doses of anti-vascular endothelial growth factors (aflibercept, bevacizumab, conbercept, ranibizumab) versus laser for retinopathy of prematurity: A network meta-analysis.
    Ortiz-Seller A; Martorell P; Barranco H; Pascual-Camps I; Morcillo E; Ortiz JL
    Surv Ophthalmol; 2024; 69(4):585-605. PubMed ID: 38432359
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Network Meta-Analysis of Retreatment Rates following Bevacizumab, Ranibizumab, Aflibercept, and Laser for Retinopathy of Prematurity.
    Chang E; Josan AS; Purohit R; Patel CK; Xue K
    Ophthalmology; 2022 Dec; 129(12):1389-1401. PubMed ID: 35842190
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Chandra P
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD009734. PubMed ID: 29308602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-vascular endothelial growth factor for diabetic macular oedema: a network meta-analysis.
    Virgili G; Parravano M; Evans JR; Gordon I; Lucenteforte E
    Cochrane Database Syst Rev; 2017 Jun; 6(6):CD007419. PubMed ID: 28639415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-vascular endothelial growth factor (VEGF) drugs for treatment of retinopathy of prematurity.
    Sankar MJ; Sankar J; Mehta M; Bhat V; Srinivasan R
    Cochrane Database Syst Rev; 2016; 2():CD009734. PubMed ID: 26932750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of adverse events between intravitreal anti-VEGF and laser photocoagulation for treatment-requiring retinopathy of prematurity: a systematic review.
    Tsiropoulos GN; Seliniotaki AK; Haidich AB; Ziakas N; Mataftsi A
    Int Ophthalmol; 2023 Mar; 43(3):1027-1062. PubMed ID: 36214992
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison in Retreatments between Bevacizumab and Ranibizumab Intravitreal Injections for Retinopathy of Prematurity: A Multicenter Study.
    Patel NA; Acaba-Berrocal LA; Hoyek S; Fan KC; Martinez-Castellanos MA; Baumal CR; Harper CA; Berrocal AM;
    Ophthalmology; 2023 Apr; 130(4):373-378. PubMed ID: 36396121
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Bevacizumab, Ranibizumab, and Laser Photocoagulation in the Treatment of Retinopathy of Prematurity in Turkey.
    Gunay M; Sukgen EA; Celik G; Kocluk Y
    Curr Eye Res; 2017 Mar; 42(3):462-469. PubMed ID: 27420302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of four anti-vascular endothelial growth factor agents and laser treatment for retinopathy of prematurity: A network meta-analysis.
    Xu Y; Deng G; Zhang J; Zhu J; Liu Z; Xu F; Zhou D
    Biomol Biomed; 2023 Nov; 24(4):676-687. PubMed ID: 37976345
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retinal Detachment after Treatment of Retinopathy of Prematurity with Laser versus Intravitreal Anti-Vascular Endothelial Growth Factor.
    Barry GP; Yu Y; Ying GS; Tomlinson LA; Lajoie J; Fisher M; Binenbaum G;
    Ophthalmology; 2021 Aug; 128(8):1188-1196. PubMed ID: 33387554
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in Serum Concentrations of Vascular Endothelial Growth Factors-A and B after Intravitreal Injection of Ranibizumab and Conbercept for Retinopathy of Prematurity.
    Zhang H; Yang X; Zheng F; Wan S; Xu Y
    Ophthalmologica; 2023; 246(2):81-89. PubMed ID: 36709750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy comparison of anti-vascular endothelial growth factor drugs for the treatment of type 1 retinopathy of prematurity: A network meta-analysis of randomised controlled trials.
    Zhou M; Hashimoto K; Liu W; Cai Y; Liang J; Shi X; Zhao M
    Graefes Arch Clin Exp Ophthalmol; 2024 May; 262(5):1409-1419. PubMed ID: 37815595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-vascular Endothelial Growth Factor Treatment of Retinopathy of Prematurity: Efficacy, Safety, and Anatomical Outcomes.
    Kang HG; Choi EY; Byeon SH; Kim SS; Koh HJ; Lee SC; Kim M
    Korean J Ophthalmol; 2018 Dec; 32(6):451-458. PubMed ID: 30549468
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Systemic Adverse Events after Intravitreal Bevacizumab, Ranibizumab, and Aflibercept in Routine Clinical Practice.
    Maloney MH; Payne SR; Herrin J; Sangaralingham LR; Shah ND; Barkmeier AJ
    Ophthalmology; 2021 Mar; 128(3):417-424. PubMed ID: 32781110
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of bevacizumab, ranibizumab and aflibercept in retinopathy of prematurity treatment.
    Süren E; Özkaya D; Çetinkaya E; Kalaycı M; Yiğit K; Kücük MF; Erol MK
    Int Ophthalmol; 2022 Jun; 42(6):1905-1913. PubMed ID: 35094229
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RATES AND RISK FACTORS FOR RECURRENCE OF RETINOPATHY OF PREMATURITY AFTER LASER OR INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR MONOTHERAPY.
    Ling KP; Liao PJ; Wang NK; Chao AN; Chen KJ; Chen TL; Hwang YS; Lai CC; Wu WC
    Retina; 2020 Sep; 40(9):1793-1803. PubMed ID: 31800460
    [TBL] [Abstract][Full Text] [Related]  

  • 18. New trends in intravitreal anti-VEGF therapy for ROP.
    Beccasio A; Mignini C; Caricato A; Iaccheri B; Di Cara G; Verrotti A; Cagini C
    Eur J Ophthalmol; 2022 May; 32(3):1340-1351. PubMed ID: 35040348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Intravitreal Bevacizumab, Intravitreal Ranibizumab and Laser Photocoagulation for Treatment of Type 1 Retinopathy of Prematurity in Turkish Preterm Children.
    Kabataş EU; Kurtul BE; Altıaylık Özer P; Kabataş N
    Curr Eye Res; 2017 Jul; 42(7):1054-1058. PubMed ID: 28128986
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of efficacy between anti-vascular endothelial growth factor (VEGF) and laser treatment in Type-1 and threshold retinopathy of prematurity (ROP).
    Li Z; Zhang Y; Liao Y; Zeng R; Zeng P; Lan Y
    BMC Ophthalmol; 2018 Jan; 18(1):19. PubMed ID: 29378530
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.